SOURCE: Bioheart, Inc.

Bioheart, Inc.

March 21, 2014 08:00 ET

Bioheart, Inc. to Present at American Association of Orthopedic Medicine on Cell Therapy

SUNRISE, FL--(Marketwired - Mar 21, 2014) - Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the 31st American Association of Orthopedic Medicine Annual Conference (AAOM) Conference and Scientific Seminar. Co-sponsored by the American Board of Quality Assurance and Utilization Review Physicians, Inc. (ABQAURP), the conference, titled "Sports, Spine and Beyond: Latest Advances in Regenerative Orthopedic Medicine," will focus on the newest breakthroughs in the field of orthopedic medicine.

Kristin Comella, Bioheart's Chief Scientific Officer, will present a summary of data on the use of stem cells to treat a variety of indications. She will chair the pre-conference session titled "Clinical Applications of Regenerative Medicine." Other speakers in the session include Joe Purita, MD, Michael Brown, MD and more.

The 31st AAOM Annual Conference and Scientific Seminar will take place April 9-12, 2014 at the Hilton Clearwater Beach Resort in Clearwater, Florida. It will provide both lectures and practical instruction workshops on the diagnosis and treatment of a variety of orthopedic medicine concerns. There will be anatomical reviews, discussion of research, RIT lectures/workshops, discussion and workshops.

About Bioheart, Inc.

Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases.

Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart's goals are to improve a patient's quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart's leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

For more information on Bioheart, visit, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2012, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.

Contact Information

  • Media Contact: Carissa Matton
    Bioheart, Inc.
    13794 NW 4th Street, Suite 212
    Sunrise, Florida 33325
    Phone: 772.285.8511